Área privada
Contacto
Número total de visitas
| Visualizaciones | |
|---|---|
| Intracranial ... | 196 |
Visitas al mes
| junio 2025 | julio 2025 | agosto 2025 | septiembre 2025 | octubre 2025 | noviembre 2025 | diciembre 2025 | |
|---|---|---|---|---|---|---|---|
| Intracranial ... | 21 | 2 | 5 | 12 | 4 | 10 | 1 |
Visitas al fichero
| Visualizaciones | |
|---|---|
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula5.pdf | 176 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021.pdf | 73 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula3.pdf | 50 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_figura1.pdf | 40 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula2.pdf | 32 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula1.pdf | 30 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula4.pdf | 20 |
Países con más visualizaciones
| Visualizaciones | |
|---|---|
| Estados Unidos | 91 |
| Singapur | 23 |
| Brasil | 17 |
| España | 14 |
| Alemania | 9 |
| Canadá | 6 |
| Hong Kong | 4 |
| Argentina | 3 |
| China | 3 |
| Finlandia | 3 |
Ciudades con más visualizaciones
| Visualizaciones | |
|---|---|
| Newark | 18 |
| Singapore | 16 |
| Ashburn | 13 |
| Chandler | 11 |
| Barcelona | 7 |
| Chicago | 5 |
| Hong Kong | 4 |
| Nuremberg | 4 |
| Düsseldorf | 3 |
| Los Angeles | 3 |
